SABSW

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SABSW

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	20 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/21	06 : 45	GlobeNewswire Inc.	SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/21	05 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/06	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/16	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Provides SAB-142 Trial Update	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/08	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at INNODIA Annual Meeting	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/04	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/03/29	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/03/25	23 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/23	22 : 00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/08	22 : 00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/02	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Executive Leadership Change	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/01/24	07 : 58	GlobeNewswire Inc.	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/01/03	06 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/29	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/20	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/14	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/14	21 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/09	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/24	20 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/19	20 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/05	20 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/02	20 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/08/21	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/06/21	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/30	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/19	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/16	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/12	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/09	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform	NASDAQ:SABSW	SAB Biotherapeutics Inc